Obesity and non-alcoholic fatty liver disease (NAFLD) have been associated with an increase in IL-17A, which is produced in the intestinal mucosa, and its levels are modulated by microbiome composition [29,30]. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.